Open AccessEvaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer’s Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant
Author(s) -
Carsten T. Beuckmann,
Hiroyuki Suzuki,
Erik S. Musiek,
Takashi Ueno,
Toshitaka Sato,
Masahiro Bando,
Yoshihide Osada,
Margaret Moline
Publication year - 2021
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-201054
Subject(s) - circadian rhythm , endocrinology , wakefulness , medicine , orexin , rhythm , antagonist , psychology , receptor , neuroscience , neuropeptide , electroencephalography
Many patients with Alzheimer's disease (AD) display circadian rhythm and sleep-wake disturbances. However, few mouse AD models exhibit these disturbances. Lemborexant, a dual orexin receptor antagonist, is under development for treating circadian rhythm disorders in dementia.